Core Testing And FDA Approvals Will Strengthen Diagnostics

Published
25 Mar 25
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$3.63
62.2% undervalued intrinsic discount
14 Aug
US$1.37
Loading
1Y
-11.6%
7D
5.4%

Author's Valuation

US$3.6

62.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on06 Aug 25
Fair value Decreased 9.19%

The consensus price target for OPKO Health has been reduced, primarily reflecting lower revenue growth expectations and a higher discount rate, resulting in a new fair value estimate of $3.62. What's in the News Issued 2025 revenue guidance of $640–$660 million.

Shared on01 May 25
Fair value Increased 22%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 18%

AnalystConsensusTarget has decreased revenue growth from 6.0% to 4.9%, decreased future PE multiple from 123.3x to 76.6x and decreased shares outstanding growth rate from 0.1% to -0.0%.